- Home
- XTKG vs ABP Comparison
XTKG vs ABP Comparison
Compare XTKG & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTKG
- ABP
- Stock Information
- Founded
- XTKG 1997
- ABP 2004
- Country
- XTKG Singapore
- ABP United States
- Employees
- XTKG N/A
- ABP N/A
- Industry
- XTKG
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- XTKG
- ABP Health Care
- Exchange
- XTKG NYSE
- ABP Nasdaq
- Market Cap
- XTKG 16.3M
- ABP 15.5M
- IPO Year
- XTKG 2019
- ABP N/A
- Fundamental
- Price
- XTKG $1.52
- ABP $0.21
- Analyst Decision
- XTKG
- ABP Strong Buy
- Analyst Count
- XTKG 0
- ABP 1
- Target Price
- XTKG N/A
- ABP $4.00
- AVG Volume (30 Days)
- XTKG 107.1K
- ABP 5.6M
- Earning Date
- XTKG 07-07-2025
- ABP 08-18-2025
- Dividend Yield
- XTKG N/A
- ABP N/A
- EPS Growth
- XTKG N/A
- ABP N/A
- EPS
- XTKG N/A
- ABP N/A
- Revenue
- XTKG $11,611,442.00
- ABP $183,000.00
- Revenue This Year
- XTKG N/A
- ABP N/A
- Revenue Next Year
- XTKG N/A
- ABP N/A
- P/E Ratio
- XTKG N/A
- ABP N/A
- Revenue Growth
- XTKG N/A
- ABP 88.66
- 52 Week Low
- XTKG $0.53
- ABP $0.15
- 52 Week High
- XTKG $11.60
- ABP $11.19
- Technical
- Relative Strength Index (RSI)
- XTKG 50.52
- ABP N/A
- Support Level
- XTKG $1.25
- ABP N/A
- Resistance Level
- XTKG $2.24
- ABP N/A
- Average True Range (ATR)
- XTKG 0.25
- ABP 0.00
- MACD
- XTKG -0.01
- ABP 0.00
- Stochastic Oscillator
- XTKG 27.27
- ABP 0.00
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries. It generates revenue from service lines: Application development services; Consulting and technical support services; Subscription services; Trading; and Others, of which maximum revenue is derived from Application development services. Geographically, all of the company's revenue is derived from PRC.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.